CWC
CRSP icon

Carolinas Wealth Consulting’s CRISPR Therapeutics CRSP Stock Holding History

Carolinas Wealth Consulting’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74
Closed -$2.52K – 193
2025
Q1 		$2.52K Buy
+74
New +$3.14K ﹤0.01% 751
2021
Q4 		– Sell
-20
Closed -$2K – 968
2021
Q3 		$2K Hold
20
– – ﹤0.01% 779
2021
Q2 		$3K Hold
20
– – ﹤0.01% 756
2021
Q1 		$2K Hold
20
– – ﹤0.01% 802
2020
Q4 		$3K Buy
+20
New +$2.36K ﹤0.01% 695

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carolinas Wealth Consulting's CRSP Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 74 shares — an estimated $2.52K sold.

Carolinas Wealth Consulting first reported a position in CRSP in Q4 2020 and held it in 5 quarters. The position peaked at $3K in Q2 2021. 434 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Carolinas Wealth Consulting reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 74 CRISPR Therapeutics shares in Q2 2025, an estimated $2.52K.
  • Carolinas Wealth Consulting first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 5 quarters.
  • Carolinas Wealth Consulting's CRISPR Therapeutics position peaked at $3K in Q2 2021.
  • 434 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.